[go: up one dir, main page]

LT2769992T - Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių - Google Patents

Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių

Info

Publication number
LT2769992T
LT2769992T LTEP14162081.5T LT14162081T LT2769992T LT 2769992 T LT2769992 T LT 2769992T LT 14162081 T LT14162081 T LT 14162081T LT 2769992 T LT2769992 T LT 2769992T
Authority
LT
Lithuania
Prior art keywords
human
receptor
high affinity
antibodies
human antibodies
Prior art date
Application number
LTEP14162081.5T
Other languages
English (en)
Inventor
Sean Stevens
Tammy T. Huang
Joel H. Martin
Jeanette L. Fairhurst
Ashique Rafique
Marcela Torres
Kevin J. Pobursky
Raymond W. Leidich
Joan A. Windsor
Warren R. Mikulka
Diana M. Ahrens
Ergang Shi
Nicholas J. Papadopoulos
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT2769992T publication Critical patent/LT2769992T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
LTEP14162081.5T 2006-10-02 2007-10-02 Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių LT2769992T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84869406P 2006-10-02 2006-10-02
US95773807P 2007-08-24 2007-08-24

Publications (1)

Publication Number Publication Date
LT2769992T true LT2769992T (lt) 2021-04-12

Family

ID=39344836

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14162081.5T LT2769992T (lt) 2006-10-02 2007-10-02 Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių

Country Status (35)

Country Link
US (4) US7605237B2 (lt)
EP (3) EP3845563A3 (lt)
JP (1) JP2010505418A (lt)
KR (1) KR101474227B1 (lt)
CN (1) CN101522716B (lt)
AU (1) AU2007314522C9 (lt)
BR (1) BRPI0719953B8 (lt)
CA (1) CA2664343C (lt)
CO (1) CO6160305A2 (lt)
CR (1) CR10689A (lt)
CY (1) CY1115551T1 (lt)
DK (2) DK2769992T3 (lt)
DO (1) DOP2009000058A (lt)
ES (2) ES2466669T3 (lt)
HK (2) HK1131790A1 (lt)
HR (2) HRP20140512T1 (lt)
HU (1) HUE054090T2 (lt)
IL (1) IL197479A (lt)
LT (1) LT2769992T (lt)
MA (1) MA31138B1 (lt)
ME (1) MEP11109A (lt)
MX (1) MX2009003393A (lt)
MY (1) MY149079A (lt)
NI (1) NI200900041A (lt)
NO (1) NO347180B1 (lt)
NZ (1) NZ576040A (lt)
PL (2) PL2069403T3 (lt)
PT (2) PT2069403E (lt)
RS (2) RS61650B1 (lt)
RU (1) RU2445318C2 (lt)
SI (2) SI2769992T1 (lt)
TN (1) TN2009000110A1 (lt)
UA (1) UA98943C2 (lt)
WO (1) WO2008054606A2 (lt)
ZA (1) ZA200901617B (lt)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP3211010A1 (en) * 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
AU2014216019B2 (en) * 2008-10-29 2016-04-21 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP3871497B1 (en) * 2009-07-08 2024-02-28 Kymab Limited Rodent models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
LT3095871T (lt) 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ME02444B (me) 2010-06-22 2016-09-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispouavaju miševi
ES2612459T3 (es) * 2010-08-02 2017-05-17 Regeneron Pharmaceuticals, Inc. Ratones que producen proteínas de unión que comprenden dominios VL
PL3354280T3 (pl) 2010-10-06 2021-02-08 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny 4 (IL-4R)
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
BR112014000630A2 (pt) 2011-07-11 2017-02-14 Glenmark Pharmaceuticals Sa anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro
DK2734545T3 (en) 2011-07-18 2019-04-15 Inst Res Biomedicine NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND APPLICATIONS THEREOF
PL3572517T3 (pl) 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
JP2015512245A (ja) 2012-03-16 2015-04-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性の結合特徴を有する抗原結合タンパク質を産生するマウス
EP2825037B1 (en) 2012-03-16 2019-05-01 Regeneron Pharmaceuticals, Inc. Rodents expressing ph-sensitive immunoglobulin sequences
PL2883449T3 (pl) 2012-03-16 2018-07-31 Regeneron Pharmaceuticals, Inc. Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane gryzonie do wytwarzania tych przeciwciał
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PL2838917T3 (pl) 2012-04-20 2019-12-31 Merus N.V. Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
BR112015003590A8 (pt) 2012-08-21 2017-10-31 Sanofi Sa Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CN105026427B (zh) * 2013-02-20 2019-12-24 依奈特制药公司 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤
SI2840892T1 (en) * 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
EP2968541A4 (en) 2013-03-15 2017-02-08 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014284235B2 (en) 2013-06-21 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
SG11201606051YA (en) * 2014-02-19 2016-09-29 Jody Berry Marburg monoclonal antibodies
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
MX2016012274A (es) 2014-03-21 2017-05-23 Regeneron Pharma Animales no humanos que producen proteinas de union de dominio simple.
RU2739952C2 (ru) 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3265494A4 (en) 2015-03-06 2018-12-05 Sorrento Therapeutics, Inc. Antibody therapeutics that bind jag1
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
CA3232651A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
HRP20211510T1 (hr) 2015-06-01 2021-12-24 Medimmune, Llc Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
IL260413B2 (en) 2016-01-13 2024-01-01 Medimmune Llc A method for treating type A influenza
ES2983475T3 (es) 2016-02-19 2024-10-23 Regeneron Pharma Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3506931B1 (en) 2016-09-01 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
EP3515465B1 (en) 2016-09-22 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
US20190240316A1 (en) * 2016-10-17 2019-08-08 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN107216388B (zh) * 2017-08-07 2020-05-05 广州泰诺迪生物科技有限公司 一种治疗丙型肝炎病毒药物的制备方法和用途
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
AU2019308205A1 (en) * 2018-07-16 2020-11-19 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
WO2020038454A1 (zh) 2018-08-24 2020-02-27 江苏恒瑞医药股份有限公司 结合人il-4r的抗体、其抗原结合片段及其医药用途
EP3878868B1 (en) * 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN111514292B (zh) * 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
JP2022526738A (ja) 2019-03-21 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ
AU2020271012A1 (en) * 2019-04-08 2021-09-09 Phanes Therapeutics, Inc. Humanized anti-DLL3 chimeric antigen receptors and uses thereof
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
CN112279914A (zh) * 2019-07-25 2021-01-29 苏州丁孚靶点生物技术有限公司 Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MX2022010217A (es) 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
KR20220147642A (ko) * 2020-02-27 2022-11-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Il4r에 결합하는 항체 및 이의 용도
US20230102151A1 (en) 2020-03-27 2023-03-30 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4132658A4 (en) * 2020-04-10 2024-08-21 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
MX2022014440A (es) 2020-05-22 2023-02-27 Regeneron Pharma Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
WO2022015049A1 (ko) 2020-07-17 2022-01-20 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
WO2022076289A1 (en) 2020-10-05 2022-04-14 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
US20240075158A1 (en) 2020-12-22 2024-03-07 Jiangsu Hengrui Pharmaceutical Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
KR20230142724A (ko) * 2021-01-08 2023-10-11 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
WO2023009437A1 (en) 2021-07-26 2023-02-02 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
EP4380979A1 (en) * 2021-08-05 2024-06-12 Eli Lilly and Company Human interleukin-4 receptor alpha antibodies
JP2024532263A (ja) 2021-08-23 2024-09-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法
EP4419557A1 (en) 2021-10-20 2024-08-28 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
EP4457245A1 (en) 2021-12-30 2024-11-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
CN118678972A (zh) 2022-01-29 2024-09-20 上海盛迪医药有限公司 糖皮质激素的药物偶联物
AU2023228815A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
EP4518839A2 (en) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
KR20250004863A (ko) 2022-05-02 2025-01-08 리제너론 파아마슈티컬스, 인크. 항-인터류킨-4 수용체(il-4r) 항체 제형
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
US20240360232A1 (en) 2023-03-22 2024-10-31 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
US20240350626A1 (en) 2023-03-27 2024-10-24 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186A (en) 1850-03-19 fetchec
US809A (en) 1838-06-27 Improved mode of changing the poles of electro-magnets
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2292665B1 (en) * 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2298717B1 (en) * 2001-11-30 2015-10-28 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
MXPA06004853A (es) * 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
EP1699825A2 (en) * 2003-12-22 2006-09-13 Amgen, Inc. Methods for identifying functional antibodies
ATE395358T1 (de) * 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
ES2859825T3 (es) 2021-10-04
EP2769992B1 (en) 2020-12-30
AU2007314522A2 (en) 2009-07-02
HUE054090T2 (hu) 2021-08-30
BRPI0719953B1 (pt) 2019-04-24
ME00616B (me) 2011-12-20
RS61650B1 (sr) 2021-04-29
MY149079A (en) 2013-07-15
DOP2009000058A (es) 2009-04-30
KR20090088865A (ko) 2009-08-20
AU2007314522C1 (en) 2013-06-27
AU2007314522B8 (en) 2013-04-11
AU2007314522B2 (en) 2013-02-21
EP2069403A2 (en) 2009-06-17
CO6160305A2 (es) 2010-05-20
TN2009000110A1 (en) 2010-08-19
NZ576040A (en) 2011-06-30
NO347180B1 (no) 2023-06-19
CA2664343A1 (en) 2008-05-08
MA31138B1 (fr) 2010-02-01
HK1200846A1 (en) 2015-08-14
US7794717B2 (en) 2010-09-14
US8092802B2 (en) 2012-01-10
CY1115551T1 (el) 2017-01-04
MX2009003393A (es) 2009-05-11
US8338135B2 (en) 2012-12-25
HRP20140512T1 (hr) 2014-07-04
US20100021476A1 (en) 2010-01-28
CN101522716A (zh) 2009-09-02
NI200900041A (es) 2011-10-17
CN101522716B (zh) 2013-03-20
RS53340B (en) 2014-10-31
DK2069403T3 (da) 2014-07-28
SI2769992T1 (sl) 2021-04-30
HK1131790A1 (en) 2010-02-05
EP3845563A2 (en) 2021-07-07
AU2007314522C9 (en) 2013-08-01
IL197479A0 (en) 2011-08-01
PT2769992T (pt) 2021-03-11
AU2007314522A8 (en) 2013-04-11
NO20091758L (no) 2009-05-04
CR10689A (es) 2009-06-24
EP3845563A3 (en) 2021-11-24
US7605237B2 (en) 2009-10-20
ES2466669T3 (es) 2014-06-10
PL2069403T3 (pl) 2015-08-31
JP2010505418A (ja) 2010-02-25
HRP20210408T1 (hr) 2021-04-30
WO2008054606A3 (en) 2009-02-05
RU2009116608A (ru) 2010-11-10
PL2769992T3 (pl) 2021-08-02
BRPI0719953A2 (pt) 2014-04-29
PT2069403E (pt) 2014-07-18
US20100291107A1 (en) 2010-11-18
KR101474227B1 (ko) 2014-12-18
AU2007314522A1 (en) 2008-05-08
ZA200901617B (en) 2009-12-30
US20120135010A1 (en) 2012-05-31
RU2445318C2 (ru) 2012-03-20
UA98943C2 (ru) 2012-07-10
SI2069403T1 (sl) 2014-09-30
IL197479A (en) 2014-03-31
WO2008054606A2 (en) 2008-05-08
DK2769992T3 (da) 2021-03-22
US20080160035A1 (en) 2008-07-03
BRPI0719953B8 (pt) 2021-05-25
MEP11109A (en) 2011-12-20
EP2769992A2 (en) 2014-08-27
EP2069403B1 (en) 2014-05-07
EP2769992A3 (en) 2015-01-21
CA2664343C (en) 2016-04-26

Similar Documents

Publication Publication Date Title
HK1200846A1 (en) High affinity human antibodies to human il-4 receptor il-4
HRP20130467T1 (en) High affinity human antibodies to human il-4 receptor
HUS1700029I1 (hu) Nagy affinitású PCSK9 elleni humán testek
IL196701A0 (en) HUMAN ANTIBODIES TO ErbB2
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
IL193604A0 (en) Methods of using antibodies against human il-22
IL197937A0 (en) Antibodies to lymphotoxin-alpha
ZA200906516B (en) Novel human anti-R7V antibodies and uses thereof
ZA200902346B (en) Antibodies to lymphotoxin-alpha
ZA200809771B (en) High affinity antibodies to human IL-6 receptor
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina